This study is a multi-centre randomized controlled, open label, phase II trial for patients
with de-novo GBM.
Eligible patients will be randomized between arm A and arm B:
Arm A (standard): Radiotherapy and chemotherapy according to standard protocol for newly
diagnosed GBM. This consists of 30 daily fractions of 2 Gy or 33 fractions in 1.8 Gy to the
tumor and surrounding margin in combination with temozolomide 75 mg/m² per os daily (po qd)
and six adjuvant cycles of temozolomide 150
Arm B (experimental): Standard treatment as described under arm A combined with daily intake
of 400mg CQ. CQ will start with one week before the start of radiotherapy and end on the last
day of radiotherapy.
In a single centre exploratory substudy, thirty subjects sequentially recruited within
MAASTRO clinic randomized to arm B will be invited to receive two 3-[18F]fluoro-
2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1- yl)propan-1-ol PET-scans
([18F]HX4 ). The first on day -6 (start CQ), the second on day 0 (before the start
radiotherapy and TMZ).